Loading..

Mirati Therapeutics, Inc. (MRTX) Report Analysis

Corporate Events

Negative

Mirati Therapeutics, Inc.(NasdaqGS:MRTX) droppe...

2022-06-24 00:00:00

Mirati Therapeutics, Inc.(NasdaqGS:MRTX) dropped from Russell 3000 Growth Index

Negative

Mirati Therapeutics, Inc.(NasdaqGS:MRTX) droppe...

2022-06-24 00:00:00

Mirati Therapeutics, Inc.(NasdaqGS:MRTX) dropped from Russell 1000 Growth Index

Negative

Mirati Therapeutics, Inc.(NasdaqGS:MRTX) droppe...

2022-06-24 00:00:00

Mirati Therapeutics, Inc.(NasdaqGS:MRTX) dropped from Russell Small Cap Comp Growth Index

Negative

Mirati Therapeutics, Inc.(NasdaqGS:MRTX) droppe...

2022-06-24 00:00:00

Mirati Therapeutics, Inc.(NasdaqGS:MRTX) dropped from Russell Midcap Growth Index

Negative

Mirati Therapeutics, Inc.(NasdaqGS:MRTX) droppe...

2022-06-24 00:00:00

Mirati Therapeutics, Inc.(NasdaqGS:MRTX) dropped from Russell 3000E Growth Index

Negative

Mirati Therapeutics, Inc.(NasdaqGS:MRTX) droppe...

2022-06-24 00:00:00

Mirati Therapeutics, Inc.(NasdaqGS:MRTX) dropped from Russell 2500 Growth Index

Positive

Mirati Therapeutics, Inc. Announces Results of ...

2022-06-06 12:07:00

Mirati Therapeutics, Inc. announced results of a prospective analysis from the Phase 1b cohort of the KRYSTAL-1 study evaluating intracranial ...

Positive

Mirati Therapeutics Announces Investigational A...

2022-05-26 21:00:00

Mirati Therapeutics, Inc. announced positive results from the registration-enabling Phase 2 cohort of the KRYSTAL-1 study evaluating adagrasib...

Neutral

Mirati Therapeutics, Inc. Presents at 2022 Jeff...

2022-05-26 13:12:00

Mirati Therapeutics, Inc. Presents at 2022 Jefferies Global Healthcare Conference, Jun-09-2022 10:00 AM. Venue: Marriott Marquis, New York Cit...

Neutral

Mirati Therapeutics, Inc. Presents at Goldman S...

2022-05-26 13:07:00

Mirati Therapeutics, Inc. Presents at Goldman Sachs 43rd Annual Global Healthcare Conference, Jun-16-2022 08:00 AM. Venue: Terranea Resort, Ra...

Neutral

Mirati Therapeutics, Inc. has filed a Shelf Reg...

2022-05-20 00:00:00

Mirati Therapeutics, Inc. has filed a Shelf Registration in the amount of $668.498849 million. Security Name: Common Stock Securities Offe...

Positive

Mirati Therapeutics, Inc. Submits Marketing Aut...

2022-05-19 20:30:00

Mirati Therapeutics, Inc. announced that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) f...

Negative

Mirati Therapeutics Appoints Laurie Stelzer as ...

2022-05-16 20:30:00

Mirati Therapeutics, Inc. announced the appointment of Laurie Stelzer as the Company's Chief Financial Officer (CFO) effective May 16, 2022. L...

Neutral

Mirati Therapeutics, Inc. Presents at The 2022 ...

2022-05-02 04:59:00

Mirati Therapeutics, Inc. Presents at The 2022 ASCO Annual Meeting, Jun-03-2022 through Jun-07-2022. Venue: McCormick Place, Chicago, Illinois...

Positive

Mirati Therapeutics, Inc. to Present New Resear...

2022-04-27 20:30:00

Mirati Therapeutics, Inc. announced the presentation of new clinical research showcasing the potential of its investigational KRASG12C inhibit...

Neutral

Mirati Therapeutics, Inc. - Special Call

2022-04-27 20:30:00

To discuss highlights from ASCO 2022

Neutral

Mirati Therapeutics, Inc. to Report Q1, 2022 Re...

2022-04-20 20:30:00

Mirati Therapeutics, Inc. announced that they will report Q1, 2022 results on May 04, 2022

Neutral

Mirati Therapeutics, Inc., Q1 2022 Earnings Cal...

2022-04-20 20:30:00

Mirati Therapeutics, Inc., Q1 2022 Earnings Call, May 04, 2022

Neutral

Mirati Therapeutics, Inc. - Shareholder/Analyst Call

2022-04-15 20:26:00

AGM

Neutral

Mirati Therapeutics, Inc., Annual General Meeti...

2022-04-15 20:26:00

Mirati Therapeutics, Inc., Annual General Meeting, May 12, 2022, at 09:00 Pacific Standard Time. Agenda: To elect the ten nominees for directo...

Neutral

Mirati Therapeutics, Inc. Presents at Drug Disc...

2022-04-14 17:07:00

Mirati Therapeutics, Inc. Presents at Drug Discovery Chemistry Conference 2022, Apr-18-2022 through Apr-21-2022. Presentation Date & Speakers:...

Neutral

Cambridge Innovation Institute, LLC, Drug Disco...

2022-04-14 12:01:00

Cambridge Innovation Institute, LLC, Drug Discovery Chemistry Conference 2022, Apr 18, 2022 through Apr 21, 2022.

Neutral

Mirati Therapeutics, Inc. Presents at Bank of A...

2022-03-22 05:03:00

Mirati Therapeutics, Inc. Presents at Bank of America 2022 Healthcare Conference, May-10-2022 . Venue: Encore Hotel, 3121 Las Vegas Blvd. S, L...

Neutral

Bank of America Corporation, Bank of America 20...

2022-02-17 10:42:00

Bank of America Corporation, Bank of America 2022 Healthcare Conference, May 10, 2022 through May 13, 2022. Venue: Encore Hotel, 3121 Las Vega...

Neutral

Jefferies LLC, 2022 Jefferies Global Healthcare...

2022-02-14 21:00:00

Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022. Venue: Marriott Marquis, New York City, New Yor...

Neutral

The Goldman Sachs Group, Inc., Goldman Sachs 43...

2022-02-08 07:31:00

The Goldman Sachs Group, Inc., Goldman Sachs 43rd Annual Global Healthcare Conference, Jun 13, 2022 through Jun 16, 2022. Venue: Terranea Reso...

Neutral

Mirati Therapeutics, Inc. Presents at 4th Annua...

2022-02-02 21:30:00

Mirati Therapeutics, Inc. Presents at 4th Annual Guggenheim Oncology Day, Feb-09-2022 12:30 PM. Speakers: James G. Christensen, Chief Scientif...

Neutral

Guggenheim Securities, LLC, 4th Annual Guggenhe...

2022-01-24 11:50:00

Guggenheim Securities, LLC, 4th Annual Guggenheim Oncology Day, Feb 09, 2022 through Feb 11, 2022.

Neutral

American Society Of Clinical Oncology, Inc., th...

2021-12-10 06:32:00

American Society Of Clinical Oncology, Inc., The 2022 ASCO Annual Meeting, Jun 03, 2022 through Jun 07, 2022. Venue: McCormick Place, Chicago,...

Neutral

Mirati Therapeutics, Inc. Presents at 4th Annua...

2021-11-23 21:30:00

Mirati Therapeutics, Inc. Presents at 4th Annual Evercore ISI HealthCONx Virtual Conference, Dec-02-2021 02:15 PM. Speakers: Charles M. Baum, ...

Positive

Mirati Therapeutics and Verastem Oncology Partn...

2021-11-22 12:30:00

Mirati Therapeutics, Inc. and Verastem Oncology announced a non-exclusive clinical collaboration agreement to evaluate the combination of Mira...

Positive

Mirati Therapeutics, Inc. Announces Submission ...

2021-11-17 12:30:00

Mirati Therapeutics, Inc. announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administrati...

Negative

Mirati Therapeutics, Inc. has completed a Follo...

2021-11-10 00:00:00

Mirati Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $499.999875 million. Security Name: Common Stock Sec...

Neutral

Mirati Therapeutics, Inc. Presents at Stifel 20...

2021-11-09 14:10:00

Mirati Therapeutics, Inc. Presents at Stifel 2021 Virtual Healthcare Conference, Nov-16-2021 11:20 AM. Venue: New York, New York, United State...

Negative

Mirati Therapeutics, Inc. has filed a Follow-on...

2021-11-09 00:00:00

Mirati Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $500 million. Security Name: Common Stock Security Type:...

Neutral

Mirati Therapeutics, Inc. to Report Q3, 2021 Re...

2021-11-01 20:30:00

Mirati Therapeutics, Inc. announced that they will report Q3, 2021 results on Nov 08, 2021

Neutral

Mirati Therapeutics, Inc., Q3 2021 Earnings Cal...

2021-11-01 20:30:00

Mirati Therapeutics, Inc., Q3 2021 Earnings Call, Nov 08, 2021

Negative

Mirati Therapeutics, Inc. Announces Executive Changes

2021-11-01 11:33:00

On October 28, 2021, it was determined that Daniel R. Faga would cease serving as the Executive Vice President, Chief Operating Officer and pr...

Neutral

SVB Leerink LLC, 11th SVB Leerink Annual Global...

2021-10-29 14:57:00

SVB Leerink LLC, 11th SVB Leerink Annual Global Healthcare Conference 2022, Feb 14, 2022 through Feb 18, 2022. Venue: New York, New York, Unit...

Neutral

Mirati Therapeutics, Inc. Announces Non-Exclusi...

2021-10-07 20:30:00

Mirati Therapeutics, Inc. announced a non-exclusive clinical collaboration agreement with Sanofi to evaluate the combination of adagrasib, the...

Neutral

Mirati Therapeutics, Inc. Presents at 2021 AACR...

2021-10-01 12:36:00

Mirati Therapeutics, Inc. Presents at 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics, Oct-0...

Positive

Mirati Therapeutics, Inc. announces results fro...

2021-09-20 12:20:00

Mirati Therapeutics, Inc. announced results from a post hoc exploratory analysis of the Phase 2 study, MRTX-500. Results showed durable respon...

Negative

Mirati Therapeutics, Inc. Announces Changes in ...

2021-09-20 12:11:00

On September 20, 2021, Charles M. Baum, M.D., Ph.D., transitioned from President and Chief Executive Officer and principal executive officer o...

Negative

Mirati Therapeutics Appoints David Meek to BOD

2021-09-20 11:55:00

Mirati Therapeutics, Inc. announced the appointment of David Meek as Chief Executive Officer (CEO), effective immediately. Mr. Meek will also ...

Positive

Mirati Therapeutics, Inc. Announces Positive Ph...

2021-09-20 11:30:00

Mirati Therapeutics, Inc. announced positive topline results from the potentially registration-enabling cohort of the Phase 2 KRYSTAL-1 study,...

Positive

Mirati Therapeutics Presents Positive Clinical ...

2021-09-19 13:47:00

Mirati Therapeutics, Inc. announced results from a cohort of the Phase 1/2 KRYSTAL–1 study evaluating adagrasib at the 600mg BID dose as both ...

Neutral

Mirati Therapeutics, Inc. Presents at 3rd Annua...

2021-09-16 13:29:00

Mirati Therapeutics, Inc. Presents at 3rd Annual RAS Targeted Drug Development Summit, Sep-21-2021 through Sep-23-2021. Presentation Date & Sp...

Neutral

Mirati Therapeutics, Inc. - Analyst/Investor Day

2021-09-15 20:15:00

To discuss the study results to be presented at the 2021 European Society of Medical Oncology (ESMO) Congress along with other matters

Neutral

Evercore Inc., 4th Annual Evercore ISI HealthCO...

2021-08-24 20:29:00

Evercore Inc., 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov 29, 2021 through Dec 03, 2021.

Neutral

Mirati Therapeutics, Inc. Presents at European ...

2021-08-23 12:06:00

Mirati Therapeutics, Inc. Presents at European Society for Medical Oncology Virtual Congress 2021, Sep-16-2021 through Sep-21-2021. Venue: Par...

Neutral

American Association For Cancer Research, Natio...

2021-08-11 12:00:00

American Association For Cancer Research, National Cancer Institute, The European Organisation For Research and Treatment of Cancer (eortc), 2...

Neutral

Mirati Therapeutics, Inc. Presents at Patient A...

2021-08-10 13:24:00

Mirati Therapeutics, Inc. Presents at Patient Assistance and Access Programs Conference, Aug-17-2021 03:15 PM. Speakers: Kelly Pitt, Executive...

Neutral

Informa plc, Patient Assistance and Access Prog...

2021-08-10 13:10:00

Informa plc, Patient Assistance and Access Programs Conference, Aug 17, 2021 through Aug 19, 2021.

Negative

Mirati Therapeutics, Inc. has filed a Follow-on...

2021-08-05 00:00:00

Mirati Therapeutics, Inc. has filed a Follow-on Equity Offering. Security Name: Common Stock Security Type: Common Stock Securities Offer...

Neutral

Stifel, Nicolaus & Company, Incorporated, Stife...

2021-07-08 08:44:00

Stifel, Nicolaus & Company, Incorporated, Stifel 2021 Virtual Healthcare Conference, Nov 15, 2021 through Nov 17, 2021. Venue: New York, New ...

Neutral

Mirati Therapeutics, Inc. has filed a Shelf Reg...

2021-07-02 00:00:00

Mirati Therapeutics, Inc. has filed a Shelf Registration. Security Name: Common Stock Security Name: Preferred Stock Security Name: D...

Negative

Mirati Therapeutics, Inc. has filed a Follow-on...

2021-07-02 00:00:00

Mirati Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $500 million. Security Name: Common Stock Security Type: ...

Negative

Mirati Therapeutics, Inc. has withdrawn its Fol...

2021-07-02 00:00:00

Mirati Therapeutics, Inc. has withdrawn its Follow-on Equity Offering in the amount of $200 million. Security Name: Common Stock Security ...

Neutral

Mirati Therapeutics, Inc. has filed a Shelf Reg...

2021-07-02 00:00:00

Mirati Therapeutics, Inc. has filed a Shelf Registration in the amount of $416.1 million. Security Name: Common Stock Securities Offered: ...

Negative

Mirati Therapeutics, Inc.(NasdaqGS:MRTX) dropped from Russell 3000 Growth Index

2022-06-24 00:00:00

Mirati Therapeutics, Inc.(NasdaqGS:MRTX) dropped from Russell 3000 Growth Index

Negative

Mirati Therapeutics, Inc.(NasdaqGS:MRTX) dropped from Russell 1000 Growth Index

2022-06-24 00:00:00

Mirati Therapeutics, Inc.(NasdaqGS:MRTX) dropped from Russell 1000 Growth Index

Negative

Mirati Therapeutics, Inc.(NasdaqGS:MRTX) dropped from Russell Small Cap Comp Growth Index

2022-06-24 00:00:00

Mirati Therapeutics, Inc.(NasdaqGS:MRTX) dropped from Russell Small Cap Comp Growth Index

Negative

Mirati Therapeutics, Inc.(NasdaqGS:MRTX) dropped from Russell Midcap Growth Index

2022-06-24 00:00:00

Mirati Therapeutics, Inc.(NasdaqGS:MRTX) dropped from Russell Midcap Growth Index

Negative

Mirati Therapeutics, Inc.(NasdaqGS:MRTX) dropped from Russell 3000E Growth Index

2022-06-24 00:00:00

Mirati Therapeutics, Inc.(NasdaqGS:MRTX) dropped from Russell 3000E Growth Index

Negative

Mirati Therapeutics, Inc.(NasdaqGS:MRTX) dropped from Russell 2500 Growth Index

2022-06-24 00:00:00

Mirati Therapeutics, Inc.(NasdaqGS:MRTX) dropped from Russell 2500 Growth Index

Positive

Mirati Therapeutics, Inc. Announces Results of A Prospective Analysis from the Phase 1B Cohort of the KRYSTAL-1

2022-06-06 12:07:00

Mirati Therapeutics, Inc. announced results of a prospective analysis from the Phase 1b cohort of the KRYSTAL-1 study evaluating intracranial (IC) responses of adagrasib in patients with KRASG12C-mutated non-small cell lung cancer (NSCLC) with active and untreated central nervous system (CNS) metastases. This is the first clinical data demonstrating CNS-specific activity of a KRASG12C inhibitor in patients with NSCLC with active and untreated CNS metastases. Findings show that approximately one third of the patients had an IC response in patients with CNS metastases, consistent with what was observed systemically in this cohort. The data will be presented as a late-breaking oral presentation in the session titled, “Clinical Science Symposium/Including the Excluded: Advancing Care for All Patients With Lung Cancer” at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting from 5:30 to 5:42 PM ET/4:30 to 4:42 PM CT (Abstract #LBA9009). Results of Prospective Analysis: With a median follow up of 6.6 months (data cutoff date December 2021), 25 patients with active, untreated CNS metastases were enrolled in the study and treated with adagrasib 600 mg BID. Of the radiographically evaluable patients (n=19), results showed an IC objective response rate of 32% (6/19) by modified response assessment in neuro-oncology-brain metastases (modified RANO-BM) by blinded independent central review. In this analysis, three patients achieved a complete response and three patients achieved a partial response. The IC disease control rate was 84% (16/19, including 10 patients with stable disease). The median IC duration of response was not reached (95% confidence interval:4.1 - not evaluable). Concordance of disease control between systemic and IC responses was 88% (14/16). For all patients enrolled, median overall survival was not reached. Cerebrospinal fluid (CSF) samples were obtained from two patients for whom regression of CNS metastases was observed; adagrasib CSF/free plasma concentration ratios (Kp,uu: 0.47) were consistent with other agents with known CNS penetration and activity. The safety profile of adagrasib in this study was consistent with the overall population with no new safety signals observed. Grade 1 and 2 treatment related adverse events (TRAEs) occurred in 60% of patients. Grade 3 TRAEs occurred in 36% of patients, and there were no Grade 4/5 TRAEs. Central nervous system metastases occur in 27% to 42% of patients with KRAS -mutated NSCLC at diagnosis. Mirati also presented results from the registration-enabling Phase 2 cohort of the KRYSTAL-1 study evaluating adagrasib in patients with pre-treated NSCLC harboring a KRAS mutation during the Lung Cancer-Non-Small Cell Metastatic session at ASCO on June 3, 2022. Central Nervous System (CNS) Metastases in KRAS-Mutated Lung Cancer: The brain, along with the bone, adrenals, and liver are common sites of extra-thoracic metastases in NSCLC. CNS metastases occur in 27-42% of patients with KRAS G12C-mutated NSCLC at diagnosis. Additionally, patients with CNS metastases and KRAS-mutated NSCLC may have poor outcomes, with median overall survival ranging of approximately five months.

Positive

Mirati Therapeutics Announces Investigational Adagrasib Delivers Positive Results in Registration-Enabling Study of Patients with KRASG12C-Mutated Advanced Non-Small Cell Lung Cancer

2022-05-26 21:00:00

Mirati Therapeutics, Inc. announced positive results from the registration-enabling Phase 2 cohort of the KRYSTAL-1 study evaluating adagrasib 600 mg BID in patients with non-small cell lung cancer (NSCLC) harboring the KRASG12C mutation who have received at least one prior systemic therapy. Findings will be presented on June 3 at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, as an oral presentation during the "Lung Cancer – Non-Small Cell Metastatic" session from 2:24 to 2:36 PM ET/1:24 to 1:36 PM CT (Abstract #9002). The Company also presented results from an exploratory, retrospective subgroup analysis from the Phase 2 NSCLC cohort of the KRYSTAL-1 study evaluating adagrasib in patients with KRASG12C-mutated NSCLC and stable,previously treated central nervous system (CNS) metastases (n=33). These results showed CNS-specific activity, including a 33% intracranial (IC) ORR by response assessment in neuro-oncology-brain metastases (modified RANO-BM). The IC DCR was 85% (95% CI: 68 – 95). In addition to these results, the Company reported updated findings from a pooled analysis in a total of 132 patients from the KRYSTAL-1 study, including the registrational Phase 2 and Phase 1/1b NSCLC cohorts evaluating adagrasib at a dose of 600mg BID. The adagrasib New Drug Application is currently being reviewed by the U.S. Food and Drug Administration (FDA) for Accelerated Approval (Subpart H) as a treatment for patients with NSCLC harboring the KRASG12C mutation who have received at least one prior systemic therapy. Adagrasib has also received Breakthrough Therapy Designation status from the FDA for the same indication. The Company has an ongoing confirmatory Phase 3 trial, KRYSTAL-12, evaluating adagrasib versus docetaxel who have been previously treated for metastatic NSCLC with a KRASG12C mutation.

Neutral

Mirati Therapeutics, Inc. Presents at 2022 Jefferies Global Healthcare Conference, Jun-09-2022 10:00 AM

2022-05-26 13:12:00

Mirati Therapeutics, Inc. Presents at 2022 Jefferies Global Healthcare Conference, Jun-09-2022 10:00 AM. Venue: Marriott Marquis, New York City, New York, United States. Speakers: David D. Meek, CEO & Director.

Neutral

Mirati Therapeutics, Inc. Presents at Goldman Sachs 43rd Annual Global Healthcare Conference, Jun-16-2022 08:00 AM

2022-05-26 13:07:00

Mirati Therapeutics, Inc. Presents at Goldman Sachs 43rd Annual Global Healthcare Conference, Jun-16-2022 08:00 AM. Venue: Terranea Resort, Rancho Palos Verdes, California, United States. Speakers: David D. Meek, CEO & Director.

Neutral

Mirati Therapeutics, Inc. has filed a Shelf Registration in the amount of $668.498849 million.

2022-05-20 00:00:00

Mirati Therapeutics, Inc. has filed a Shelf Registration in the amount of $668.498849 million. Security Name: Common Stock Securities Offered: 11,214,542 Transaction Features: ESOP Related Offering

Positive

Mirati Therapeutics, Inc. Submits Marketing Authorization Application to the European Medicines Agency for Investigational adagrasib as a Treatment

2022-05-19 20:30:00

Mirati Therapeutics, Inc. announced that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for adagrasib for the treatment of patients with non-small cell lung cancer (NSCLC) harboring the KRASG12C mutation who have received at least one prior systemic therapy. The MAA is supported by data from the registration enabling cohort of the Phase 2 KRYSTAL-1 study evaluating adagrasib 600mg BID in patients with advanced NSCLC harboring the KRASG12C mutation following prior treatment with immunotherapy and chemotherapy, either together or sequentially. The Company reported positive topline data from this cohort in September 2021 and plans to present detailed results at the upcoming 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. The adagrasib New Drug Application (NDA) is currently being reviewed by the U.S. Food and Drug Administration (FDA) for Accelerated Approval (Subpart H) as a treatment for patients with NSCLC harboring the KRASG12C mutation who have received at least one prior systemic therapy. The application is being reviewed under the FDA Real Time Oncology Review (RTOR) pilot program, which aims to explore a more efficient review process that ensures safe and effective treatments are made available to patients as early as possible. Adagrasib has also achieved Breakthrough Therapy Designation in the U.S. as a potential treatment for patients with NSCLC harboring the KRASG12C mutation who have received at least one prior systemic therapy.

Negative

Mirati Therapeutics Appoints Laurie Stelzer as Chief Financial Officer

2022-05-16 20:30:00

Mirati Therapeutics, Inc. announced the appointment of Laurie Stelzer as the Company's Chief Financial Officer (CFO) effective May 16, 2022. Laurie will report to the Company's Chief Executive Officer, David Meek. Laurie joins the Company most recently from Arena Pharmaceuticals, Inc. (acquired by Pfizer) where she served as Executive Vice President and CFO since 2020. She brings 25 years of biopharma industry experience to her role in leading the company's finance functions. Prior to joining Arena, Laurie was the CFO at Halozyme Therapeutics where she led the finance, information technology, business development, project management and site operations organizations. Vickie Reed, Mirati's Chief Accounting Officer, filled the role of Mirati's Principal Accounting Officer and on an interim basis, the Principal Financial Officer, and will be retiring from Mirati later this year.

Neutral

Mirati Therapeutics, Inc. Presents at The 2022 ASCO Annual Meeting, Jun-03-2022 through Jun-07-2022

2022-05-02 04:59:00

Mirati Therapeutics, Inc. Presents at The 2022 ASCO Annual Meeting, Jun-03-2022 through Jun-07-2022. Venue: McCormick Place, Chicago, Illinois, United States. Presentation Date(s): Jun-03-2022. Jun-07-2022.

Positive

Mirati Therapeutics, Inc. to Present New Research at the 2022 ASCO Annual Meeting Showcasing Clinical Advances of Treating KRASG12C-Mutated Lung Cancer with Investigational Adagrasib

2022-04-27 20:30:00

Mirati Therapeutics, Inc. announced the presentation of new clinical research showcasing the potential of its investigational KRASG12C inhibitor, adagrasib, in a study of patients with KRASG12C-mutated non-small cell lung cancer (NSCLC) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 3 to 7, 2022 in Chicago, IL. The adagrasib New Drug Application (NDA) is currently being reviewed by the U.S. Food and Drug Administration (FDA) for Accelerated Approval (Subpart H) as a treatment for patients with NSCLC harboring the KRASG12C mutation who have received at least one prior systemic therapy. The application is being reviewed under the FDA Real Time Oncology Review (RTOR) pilot program, which aims to explore a more efficient review process that ensures safe and effective treatments are made available to patients as early as possible. Adagrasib has also achieved Breakthrough Therapy Designation in the U.S. as a potential treatment for patients with NSCLC harboring the KRASG12C mutation who have received at least one prior systemic therapy.

Neutral

Mirati Therapeutics, Inc. - Special Call

2022-04-27 20:30:00

To discuss highlights from ASCO 2022

Neutral

Mirati Therapeutics, Inc. to Report Q1, 2022 Results on May 04, 2022

2022-04-20 20:30:00

Mirati Therapeutics, Inc. announced that they will report Q1, 2022 results on May 04, 2022

Neutral

Mirati Therapeutics, Inc., Q1 2022 Earnings Call, May 04, 2022

2022-04-20 20:30:00

Mirati Therapeutics, Inc., Q1 2022 Earnings Call, May 04, 2022

Neutral

Mirati Therapeutics, Inc. - Shareholder/Analyst Call

2022-04-15 20:26:00

AGM

Neutral

Mirati Therapeutics, Inc., Annual General Meeting, May 12, 2022

2022-04-15 20:26:00

Mirati Therapeutics, Inc., Annual General Meeting, May 12, 2022, at 09:00 Pacific Standard Time. Agenda: To elect the ten nominees for director to serve for the ensuing year and until their successors are elected; to approve, on an advisory basis, compensation paid to company's executive officers; to ratify the appointment of Ernst & Young LLP as company's independent registered public accounting firm for fiscal year ending December 31, 2022; and to discuss other matters.

Neutral

Mirati Therapeutics, Inc. Presents at Drug Discovery Chemistry Conference 2022, Apr-18-2022 through Apr-21-2022

2022-04-14 17:07:00

Mirati Therapeutics, Inc. Presents at Drug Discovery Chemistry Conference 2022, Apr-18-2022 through Apr-21-2022. Presentation Date & Speakers: Apr-19-2022, Svitlana Kulyk, Associate Director, Drug Discovery. Apr-20-2022, Matthew A. Marx, Senior Vice President, Drug Discovery.

Neutral

Cambridge Innovation Institute, LLC, Drug Discovery Chemistry Conference 2022, Apr 18, 2022 through Apr 21, 2022

2022-04-14 12:01:00

Cambridge Innovation Institute, LLC, Drug Discovery Chemistry Conference 2022, Apr 18, 2022 through Apr 21, 2022.

Neutral

Mirati Therapeutics, Inc. Presents at Bank of America 2022 Healthcare Conference, May-10-2022

2022-03-22 05:03:00

Mirati Therapeutics, Inc. Presents at Bank of America 2022 Healthcare Conference, May-10-2022 . Venue: Encore Hotel, 3121 Las Vegas Blvd. S, Las Vegas, Nevada, United States. Speakers: Ryan Asay, VP & Head of Corporate Affairs, Temre Johnson, Director of Investor Relations & Corporate Communications.

Neutral

Bank of America Corporation, Bank of America 2022 Healthcare Conference, May 10, 2022 through May 13, 2022

2022-02-17 10:42:00

Bank of America Corporation, Bank of America 2022 Healthcare Conference, May 10, 2022 through May 13, 2022. Venue: Encore Hotel, 3121 Las Vegas Blvd. S, Las Vegas, Nevada, United States.

Neutral

Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022

2022-02-14 21:00:00

Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022. Venue: Marriott Marquis, New York City, New York, United States.

Neutral

The Goldman Sachs Group, Inc., Goldman Sachs 43rd Annual Global Healthcare Conference, Jun 13, 2022 through Jun 16, 2022

2022-02-08 07:31:00

The Goldman Sachs Group, Inc., Goldman Sachs 43rd Annual Global Healthcare Conference, Jun 13, 2022 through Jun 16, 2022. Venue: Terranea Resort, Rancho Palos Verdes, California, United States.

Neutral

Mirati Therapeutics, Inc. Presents at 4th Annual Guggenheim Oncology Day, Feb-09-2022 12:30 PM

2022-02-02 21:30:00

Mirati Therapeutics, Inc. Presents at 4th Annual Guggenheim Oncology Day, Feb-09-2022 12:30 PM. Speakers: James G. Christensen, Chief Scientific Officer.

Neutral

Guggenheim Securities, LLC, 4th Annual Guggenheim Oncology Day, Feb 09, 2022 through Feb 11, 2022

2022-01-24 11:50:00

Guggenheim Securities, LLC, 4th Annual Guggenheim Oncology Day, Feb 09, 2022 through Feb 11, 2022.

Neutral

American Society Of Clinical Oncology, Inc., the 2022 ASCO Annual Meeting, Jun 03, 2022 through Jun 07, 2022

2021-12-10 06:32:00

American Society Of Clinical Oncology, Inc., The 2022 ASCO Annual Meeting, Jun 03, 2022 through Jun 07, 2022. Venue: McCormick Place, Chicago, Illinois, United States.

Neutral

Mirati Therapeutics, Inc. Presents at 4th Annual Evercore ISI HealthCONx Virtual Conference, Dec-02-2021 02:15 PM

2021-11-23 21:30:00

Mirati Therapeutics, Inc. Presents at 4th Annual Evercore ISI HealthCONx Virtual Conference, Dec-02-2021 02:15 PM. Speakers: Charles M. Baum, Founder, President, Head of Research and Development & Director, David D. Meek, CEO & Director.

Positive

Mirati Therapeutics and Verastem Oncology Partner to Evaluate Adagrasib in Combination with VS-6766 in KRASG12C-Mutant Non-Small Cell Lung Cancer

2021-11-22 12:30:00

Mirati Therapeutics, Inc. and Verastem Oncology announced a non-exclusive clinical collaboration agreement to evaluate the combination of Mirati’s investigational KRASG12C inhibitor adagrasib with Verastem Oncology’s investigational RAF/MEK inhibitor VS-6766 in KRASG12C-mutant non-small cell lung cancer. The primary objective of this multi-center, single-arm, open-label Phase 1/2 trial is to determine the maximum tolerated dose and recommended Phase 2 dose for the combination of adagrasib and VS-6766 in patients with KRASG12C-mutant NSCLC. The study will also investigate the safety, tolerability and efficacy of the combination in patients who have progressed on a KRASG12C inhibitor. The trial will build on preclinical data showing deeper blockade of ERK pathway signaling resulting in enhanced anti-tumor efficacy with the combination of adagrasib and VS-6766 relative to either agent alone. Under the terms of the agreement, Verastem Oncology and Mirati will have joint oversight of the study.

Positive

Mirati Therapeutics, Inc. Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration of MRTX1719 to Treat MTAP-Deleted Cancers

2021-11-17 12:30:00

Mirati Therapeutics, Inc. announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to evaluate the Company's synthetic lethal PRMT5 inhibitor, MRTX1719, for the treatment of methylthioadenosine phosphoylase (MTAP)-deleted cancers. MRTX1719 has demonstrated in preclinical studies to be a potent, selective inhibitor of the PRMT5 /methylthioadenosine (MTA) complex. This targeting strategy leverages the abnormally elevated levels of MTA present in MTAP-deleted cancers. As a result, MRTX1719 is able to selectively target the essential PRMT5 protein in MTAP-deleted cancer cells while sparing healthy non-tumor cells. MTAP gene deletions occur in approximately 10% of all cancers including pancreatic, lung, and bladder cancers, as well as other patient populations that have limited treatment options. Preclinical data for MRTX1719 were first presented at the 2021 AACR-NCI-EORTC Virtual International Conference. The Phase 1/2 clinical development strategy for MRTX1719 is designed to establish a Phase 2 dose and assess the safety, pharmacokinetics and initial clinical activity of MRTX1719 in patients with MTAP-deleted cancers. The Company expects to initiate a Phase 1/2 clinical trial in the first quarter of 2022, pending IND clearance from the FDA.

Negative

Mirati Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $499.999875 million.

2021-11-10 00:00:00

Mirati Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $499.999875 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 3,448,275 Price\Range: $145 Discount Per Security: $7.25

Neutral

Mirati Therapeutics, Inc. Presents at Stifel 2021 Virtual Healthcare Conference, Nov-16-2021 11:20 AM

2021-11-09 14:10:00

Mirati Therapeutics, Inc. Presents at Stifel 2021 Virtual Healthcare Conference, Nov-16-2021 11:20 AM. Venue: New York, New York, United States. Speakers: Charles M. Baum, Founder, President, Head of Research and Development & Director, David D. Meek, CEO & Director.

Negative

Mirati Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $500 million.

2021-11-09 00:00:00

Mirati Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $500 million. Security Name: Common Stock Security Type: Common Stock

Neutral

Mirati Therapeutics, Inc. to Report Q3, 2021 Results on Nov 08, 2021

2021-11-01 20:30:00

Mirati Therapeutics, Inc. announced that they will report Q3, 2021 results on Nov 08, 2021

Neutral

Mirati Therapeutics, Inc., Q3 2021 Earnings Call, Nov 08, 2021

2021-11-01 20:30:00

Mirati Therapeutics, Inc., Q3 2021 Earnings Call, Nov 08, 2021

Negative

Mirati Therapeutics, Inc. Announces Executive Changes

2021-11-01 11:33:00

On October 28, 2021, it was determined that Daniel R. Faga would cease serving as the Executive Vice President, Chief Operating Officer and principal financial officer of Mirati Therapeutics, Inc. and that Joseph Leveque would cease serving as the company's Executive Vice President and Chief Medical Officer, effective as of November 1, 2021. Vickie Reed, the company's Chief Accounting Officer, will assume the role of principal financial officer effective as of November 1, 2021.

Neutral

SVB Leerink LLC, 11th SVB Leerink Annual Global Healthcare Conference 2022, Feb 14, 2022 through Feb 18, 2022

2021-10-29 14:57:00

SVB Leerink LLC, 11th SVB Leerink Annual Global Healthcare Conference 2022, Feb 14, 2022 through Feb 18, 2022. Venue: New York, New York, United States.

Neutral

Mirati Therapeutics, Inc. Announces Non-Exclusive Clinical Collaboration Agreement with Sanofi

2021-10-07 20:30:00

Mirati Therapeutics, Inc. announced a non-exclusive clinical collaboration agreement with Sanofi to evaluate the combination of adagrasib, the Company's investigational KRASG12C inhibitor, with Sanofi's investigational SHP2 inhibitor SAR442720, also known as RMC-4630. The Phase 1/2 dose escalation and expansion study will evaluate the combination in patients with previously-treated non-small cell lung cancer (NSCLC) and KRASG12C mutations.  SHP2 is upstream of KRAS and mediates cellular signaling through the RAS/MAP kinase pathway and is frequently overactive in various types of cancer. KRASG12C inhibition and SHP2 inhibition have complementary mechanisms of action and have demonstrated additive anti-tumor activity in pre-clinical models.  Under the terms of the agreement, Sanofi will be responsible for sponsoring and operating the Phase 1/2 study, and jointly with Mirati, will oversee and share costs of the study.

Neutral

Mirati Therapeutics, Inc. Presents at 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics, Oct-07-2021 through Oct-11-2021

2021-10-01 12:36:00

Mirati Therapeutics, Inc. Presents at 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics, Oct-07-2021 through Oct-11-2021. Presentation Date & Speakers: Oct-07-2021, Peter Olson. Oct-09-2021, James G. Christensen, Chief Scientific Officer.

Positive

Mirati Therapeutics, Inc. announces results from a post hoc exploratory analysis of the Phase 2 study, MRTX-500

2021-09-20 12:20:00

Mirati Therapeutics, Inc. announced results from a post hoc exploratory analysis of the Phase 2 study, MRTX-500. Results showed durable responses and long-term survival with sitravatinib in combination with nivolumab (OPDIVO®)1 in patients with second or third line non-squamous non-small cell lung cancer (NSCLC) who experienced clinical benefit on a prior checkpoint inhibitor (CPI) and subsequent disease progression (n=68). The findings (Abstract # 1191O) will be presented in an oral presentation during the NSCLC Proffered Paper Session II at the European Society for Medical Oncology Congress (ESMO) 2021. In this exploratory analysis, the median progression free survival (PFS) was 5.7 months (95% Confidence Interval, CI: 4.9, 7.6) and the median overall survival (OS) was 14.9 months (95% CI: 9.3, 21.1), with 56% and 32% of these patients alive at one year and two years, respectively. The objective response rate (ORR) was 18%, with 3% of patients achieving a complete response (CR) and 15% of patients achieving a partial response (PR). The median duration of response (DOR) was 12.8 months. The sitravatinib and nivolumab combination in this analysis was well-tolerated and consistent with what has been previously reported for this regimen in patients with non-squamous NSCLC who are CPI experienced. Grade 3/4 treatment-related adverse events (TRAEs) were reported in 66% of patients. The rate of TRAEs leading to study treatment discontinuation was 22%.

Negative

Mirati Therapeutics, Inc. Announces Changes in Chief Executive Officer

2021-09-20 12:11:00

On September 20, 2021, Charles M. Baum, M.D., Ph.D., transitioned from President and Chief Executive Officer and principal executive officer of Mirati Therapeutics, Inc. (the Company) to President, Founder and Head of Research and Development of the Company. Dr. Baum will continue to lead the Company's research and development efforts and serve as a member of the Company's Board of Directors (the Board"). On September 20, 2021, David Meek was appointed as the Company's Chief Executive Officer and principal executive officer, and Charles M. Baum, M.D., Ph.D., was appointed as the Company's President, Founder and Head of Research and Development. Mr. Meek, age 58, previously served as the President, Chief Executive Officer and Board Member of FerGene, Inc. from January 2020 to March 2021. From July 2016 to January 2020, Mr. Meek served as Chief Executive Officer of Ipsen, a public global biopharmaceutical company based in France. Prior to joining Ipsen, Mr. Meek held numerous leadership roles including serving as Executive Vice President of Oncology at Baxalta Incorporated from 2014 to 2016, serving as Chief Commercial Officer of Endocyte, Inc. from 2012 to 2014.

Negative

Mirati Therapeutics Appoints David Meek to BOD

2021-09-20 11:55:00

Mirati Therapeutics, Inc. announced the appointment of David Meek as Chief Executive Officer (CEO), effective immediately. Mr. Meek will also join the Company's Board of Directors. Charles M. Baum, M.D., Ph.D. will continue to lead the research and development (R&D) organization as president, founder and head of R&D. Dr. Baum will remain on the Company's Board of Directors. Mr. Meek has over thirty years of industry experience, where he held various global executive leadership positions in large pharmaceutical and commercial-stage biotechnology companies focused on oncology, including as CEO of Ipsen, a leading global biopharmaceutical company. David Meek most recently served as president, CEO and board member of FerGene focused on developing an innovative gene therapy for bladder cancer. During his tenure as CEO at Ipsen, Mr. Meek led the transformation of the company into a high-growth and leading global biopharmaceutical organization through the expansion of the oncology portfolio in the U.S. and Europe, and growing the R&D portfolio through internal and external innovation. Mr. Meek's prior leadership roles include serving as executive vice president and president of oncology at Baxalta from 2014 to 2016, until its acquisition by Shire plc. He was also chief commercial officer of Endocyte from 2012 to 2014. Prior to that, Mr. Meek served in various executive leadership roles at Novartis Pharma and Novartis Oncology after beginning his career at Johnson & Johnson and Janssen from 1989 to 2004. He holds a Bachelor of Arts from the University of Cincinnati. Mr. Meek has also served on the boards of Pharmaceutical Research and Manufacturers of America (PhRMA), European Federation of Pharmaceutical Industries and Associations (EFPIA), and currently serves on the boards of uniQure N.V., Entasis Therapeutics Holdings Inc. and Stargazer Pharmaceuticals.

Positive

Mirati Therapeutics, Inc. Announces Positive Phase 2 Topline Results for Investigational Adagrasib in Patients with KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

2021-09-20 11:30:00

Mirati Therapeutics, Inc. announced positive topline results from the potentially registration-enabling cohort of the Phase 2 KRYSTAL-1 study, evaluating adagrasib in patients with advanced non-small cell lung cancer harboring the KRASG12C mutation following prior systemic therapy. The analysis was completed in the intent-to-treat population, which showed adagrasib 600mg BID demonstrated an objective response rate (ORR) of 43% and a disease control rate of 80%, based on central independent review as of June 15, 2021. The median follow-up was 9 months. Importantly, 98.3% of patients received adagrasib following treatment with immunotherapy and chemotherapy. The safety and tolerability profile was consistent with previously reported findings for adagrasib in patients with advanced NSCLC. The Company plans to submit detailed results from the ongoing Phase 2 registration-enabling cohort of the KRYSTAL-1 study in previously-treated patients with KRASG12C-mutated NSCLC for presentation at a medical congress in early 2022. In addition to these topline Phase 2 results, the Company reported updated findings from the Phase 1/1b KRYSTAL-1 study evaluating adagrasib 600mg BID in all 19 patients enrolled with KRASG12C-mutated advanced NSCLC as of the June 15, 2021 data cutoff. Results showed that the investigator assessed ORR was 58%. Two of the 11 responses occurred in patients after being on treatment for more than 10 months. The median follow-up was 17.3 months. The median duration of treatment and median duration of response were 9.5 months and 12.6 months, respectively. In addition, 64% of responders were still on treatment, and continuing to respond. The median progression free survival was 8.3 months and median overall survival was not reached. Grade 3/4 treatment related adverse events were observed in 26% of patients, with one Grade 5 event.

Positive

Mirati Therapeutics Presents Positive Clinical Data with Investigational Adagrasib as Monotherapy and in Combination with Cetuximab in Patients with Kras G12c-Mutated Colorectal Cancer

2021-09-19 13:47:00

Mirati Therapeutics, Inc. announced results from a cohort of the Phase 1/2 KRYSTAL–1 study evaluating adagrasib at the 600mg BID dose as both monotherapy and in combination with cetuximab in patients with heavily pretreated colorectal cancer harboring a KRASG12C mutation. Results showed that adagrasib alone and with cetuximab demonstrated significant clinical activity and broad disease control in these patients. The findings (Abstract # LBA6) will be presented at 9:47 a.m. ET as a late-breaking oral presentation during the Presidential Symposium II session at the European Society for Medical Oncology Congress (ESMO) 2021. As of May 25, 2021, 80% of patients enrolled in the adagrasib monotheranno dtapy arm (n=46) received at least two prior lines of systemic anticancer therapies, and had a median follow up of 8.9 months. Of the evaluable patients (n=45), results showed an investigator assessed response rate (RR) of 22%, including one unconfirmed partial response (PR), and a disease control rate (DCR) of 87%; the median duration of response (DOR) was 4.2 months. In all enrolled patients, the median progression free survival (PFS) was 5.6 months (95% Confidence Interval, CI: 4.1,8.3). As of July 9, 2021, 90% patients enrolled in the adagrasib plus cetuximab arm (n=32) received at least two prior lines of systemic anticancer therapies, and had a median follow up of 7 months. Of the evaluable patients (n=28), results showed an investigator assessed RR of 43%, including two unconfirmed PRs and a DCR rate of 100%. After the data cutoff date, of the two unconfirmed PRs, follow up scans showed one patient had a confirmed PR, and the second patient progressed. At the time of the analysis, 63% (20/32) of enrolled patients remained on treatment. Adagrasib monotherapy and in combination with cetuximab was well-tolerated in this study, with a manageable safety profile. Grade 3/4 treatment related adverse events (TRAEs) were observed in 30% of patients treated with adagrasib alone, and in 16% of patients treated with the combination. Treatment related adverse events led to treatment discontinuation in 6% of patients who received combination therapy and in none (0%) of those who received adagrasib monotherapy. No Grade 5 TRAEs were observed in either treatment arm.

Neutral

Mirati Therapeutics, Inc. Presents at 3rd Annual RAS Targeted Drug Development Summit, Sep-21-2021 through Sep-23-2021

2021-09-16 13:29:00

Mirati Therapeutics, Inc. Presents at 3rd Annual RAS Targeted Drug Development Summit, Sep-21-2021 through Sep-23-2021. Presentation Date & Speakers: Sep-22-2021, Susan Yang, Adagrasib Medical Lead.

Neutral

Mirati Therapeutics, Inc. - Analyst/Investor Day

2021-09-15 20:15:00

To discuss the study results to be presented at the 2021 European Society of Medical Oncology (ESMO) Congress along with other matters

Neutral

Evercore Inc., 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov 29, 2021 through Dec 03, 2021

2021-08-24 20:29:00

Evercore Inc., 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov 29, 2021 through Dec 03, 2021.

Neutral

Mirati Therapeutics, Inc. Presents at European Society for Medical Oncology Virtual Congress 2021, Sep-16-2021 through Sep-21-2021

2021-08-23 12:06:00

Mirati Therapeutics, Inc. Presents at European Society for Medical Oncology Virtual Congress 2021, Sep-16-2021 through Sep-21-2021. Venue: Paris Expo Porte de Versailles, Paris, France. Presentation Date(s): Sep-19-2021. Sep-20-2021.

Neutral

American Association For Cancer Research, National Cancer Institute, The European Organisation For Research and Treatment of Cancer (eortc), 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics, Oct 07, 2021 through Oct 11, 2021

2021-08-11 12:00:00

American Association For Cancer Research, National Cancer Institute, The European Organisation For Research and Treatment of Cancer (eortc), 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics, Oct 07, 2021 through Oct 11, 2021.

Neutral

Mirati Therapeutics, Inc. Presents at Patient Assistance and Access Programs Conference, Aug-17-2021 03:15 PM

2021-08-10 13:24:00

Mirati Therapeutics, Inc. Presents at Patient Assistance and Access Programs Conference, Aug-17-2021 03:15 PM. Speakers: Kelly Pitt, Executive Director, Commercial Legal & Compliance.

Neutral

Informa plc, Patient Assistance and Access Programs Conference, Aug 17, 2021 through Aug 19, 2021

2021-08-10 13:10:00

Informa plc, Patient Assistance and Access Programs Conference, Aug 17, 2021 through Aug 19, 2021.

Negative

Mirati Therapeutics, Inc. has filed a Follow-on Equity Offering.

2021-08-05 00:00:00

Mirati Therapeutics, Inc. has filed a Follow-on Equity Offering. Security Name: Common Stock Security Type: Common Stock Securities Offered: 7,605,811

Neutral

Stifel, Nicolaus & Company, Incorporated, Stifel 2021 Virtual Healthcare Conference, Nov 15, 2021 through Nov 17, 2021

2021-07-08 08:44:00

Stifel, Nicolaus & Company, Incorporated, Stifel 2021 Virtual Healthcare Conference, Nov 15, 2021 through Nov 17, 2021. Venue: New York, New York, United States.

Neutral

Mirati Therapeutics, Inc. has filed a Shelf Registration.

2021-07-02 00:00:00

Mirati Therapeutics, Inc. has filed a Shelf Registration. Security Name: Common Stock Security Name: Preferred Stock Security Name: Debt Securities Security Name: Warrants Transaction Features: Omnibus/Universal Shelf Registration

Negative

Mirati Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $500 million.

2021-07-02 00:00:00

Mirati Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $500 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offering

Negative

Mirati Therapeutics, Inc. has withdrawn its Follow-on Equity Offering in the amount of $200 million.

2021-07-02 00:00:00

Mirati Therapeutics, Inc. has withdrawn its Follow-on Equity Offering in the amount of $200 million. Security Name: Common Stock Security Type: Common Stock

Neutral

Mirati Therapeutics, Inc. has filed a Shelf Registration in the amount of $416.1 million.

2021-07-02 00:00:00

Mirati Therapeutics, Inc. has filed a Shelf Registration in the amount of $416.1 million. Security Name: Common Stock Securities Offered: 2,500,000 Transaction Features: ESOP Related Offering

Fundamental Summary

The financials published by Mirati Therapeutics for Q1 were weak and discouraging. Their growth, value, and income factors performance indicate that company management are not executing well their business plan. These results suggest a challenging future for Mirati Therapeutics's stock. Therefore, we assessed them with a rating of 52 and a UNDERPERFORM recommendation.

Mirati Therapeutics reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported revenue was USD 0.709 million. Net loss was USD 188.39 million compared to USD 135.68 million a year ago. Basic loss per share from continuing operations was USD 3.4 compared to USD 2.67 a year ago.

Business Description

Mirati Therapeutics, a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase 3 clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib. Mirati Therapeutics was founded in 1995 and is headquartered in San Diego, California.

Sector Overview

Mirati Therapeutics is included in the Biotechnology according to GICS (global industry classification standard). The Biotechnology industry, which is part of the Health Care sector, includes companies primarily engaged in R&D, manufacturing, and/or marketing of products based on genetic analysis and genetic engineering. Mirati Therapeutics's industry and sector affiliation are expected to negatively affect their likelihood to overperform the market in the upcoming period, as other sectors appear more likely to benefit from the macroeconomic environment we see now.

Fundamental Highlights


Parameter Value Change Score
Assets 1,421.3 -10.5% 66
Liabilities 172.0 -10.3% 53
Price to Book 2.5 -56.5% 42
Cash & Equivalents 304.7 -26.2% 48
Equity 1,249.3 -10.6% 57
EBITDA -615.3 -9.1% 55
Total Revenues 72.8 1.0% 76
Parameter Value Change Score
Return on Equity -50.6 -19.9% 78
Net Cashflow -24.8 94.7% 56
Capital Expenditure -9.8 -0.3% 71
Asset Turnover 0.1 10.5% 89
Free Cashflow -8.5 -10.1% 58

* All values are TTM

The below chart reflects Mirati Therapeutics's birds-eye view on its performance with respect to its peers, the company's fillings as reported or to a similar industry, market cap, and country of origin. While Mirati Therapeutics's peer average final assessment score stands on 62.0, Mirati Therapeutics's score is 52.

  •  MRTX
  •  Peers average
Name Market Cap Balance Sheet Income Statement Cash Flow Rating Final Assessment mc_sort Hidden
Amgen Inc. 130.1B 69 78 81
Hold
77
77 0 1
Gilead Sciences, Inc. 78.0B 57 73 62
Underperform
60
60 1 1
Vertex Pharmaceuticals Incorporated 70.6B 78 75 71
Buy
79
79 2 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 73
Hold
72
72 3 1
BioNTech SE 34.0B 75 79 72
Buy
79
79 4 1
Seagen Inc. 32.9B 61 62 58
Underperform
57
57 5 1
Biogen Inc. 29.7B 76 70 66
Hold
74
74 6 1
Alnylam Pharmaceuticals, Inc. 17.2B 54 80 85
Hold
69
69 7 1
Incyte Corporation 16.8B 83 73 84
Buy
86
86 8 1
BioMarin Pharmaceutical Inc. 15.4B 70 82 63
Hold
74
74 9 1
United Therapeutics Corporation 10.6B 76 82 93
Strong Buy
88
88 10 1
Neurocrine Biosciences, Inc. 9.3B 68 55 63
Underperform
60
60 11 1
Exelixis, Inc. 6.7B 70 81 87
Buy
81
81 12 1
Sarepta Therapeutics, Inc. 6.5B 58 78 93
Hold
73
73 13 1
Halozyme Therapeutics, Inc. 6.3B 74 82 75
Buy
81
81 14 1
Ionis Pharmaceuticals, Inc. 5.4B 62 86 89
Buy
79
79 15 1
Ascendis Pharma A/S 5.2B 68 54 62
Underperform
60
60 16 1
Alkermes plc 5.0B 62 62 92
Hold
69
69 17 1
Cytokinetics, Incorporated 4.1B 64 66 69
Hold
65
65 18 1
Novavax, Inc. 4.0B 77 75 60
Hold
74
74 19 1
Natera, Inc. 3.6B 54 52 58
Underperform
47
47 20 1
Arrowhead Pharmaceuticals, Inc. 3.4B 71 76 70
Hold
74
74 21 1
PTC Therapeutics, Inc. 2.8B 51 73 72
Underperform
59
59 22 1
Insmed Incorporated 2.4B 55 57 82
Underperform
58
58 23 1
ACADIA Pharmaceuticals Inc. 2.3B 63 58 72
Hold
61
61 24 1
BioCryst Pharmaceuticals, Inc. 1.9B 55 66 67
Underperform
57
57 25 1
ChemoCentryx, Inc. 1.8B 61 73 87
Hold
71
71 26 1
Ironwood Pharmaceuticals, Inc. 1.8B 68 79 78
Hold
76
76 27 1
Myriad Genetics, Inc. 1.5B 52 96 59
Hold
66
66 28 1
Agios Pharmaceuticals, Inc. 1.2B 50 75 75
Hold
60
60 29 1
IVERIC bio, Inc. 1.1B 50 70 64
Underperform
54
54 30 1
FibroGen, Inc. 1.0B 73 67 84
Hold
76
76 31 1
Syndax Pharmaceuticals, Inc. 1.0B 58 62 57
Underperform
54
54 32 1
ImmunoGen, Inc. 946.1M 56 64 87
Hold
64
64 33 1
Enanta Pharmaceuticals, Inc. 922.8M 60 75 66
Hold
65
65 34 1
Deciphera Pharmaceuticals, Inc. 914.0M 61 77 94
Hold
75
75 35 1
Anavex Life Sciences Corp. 767.1M 61 75 72
Hold
67
67 36 1
Sangamo Therapeutics, Inc. 600.0M 48 76 91
Hold
65
65 37 1
AnaptysBio, Inc. 586.3M 52 68 80
Hold
60
60 38 1
Geron Corporation 566.2M 60 78 77
Hold
70
70 39 1
Mersana Therapeutics, Inc. 449.1M 58 47 65
Underperform
50
50 40 1
Inovio Pharmaceuticals, Inc. 416.9M 46 72 71
Underperform
54
54 41 1
Arbutus Biopharma Corporation 388.2M 60 67 95
Hold
71
71 42 1
Intercept Pharmaceuticals, Inc. 386.3M 57 86 96
Hold
78
78 43 1
Anika Therapeutics, Inc. 322.7M 64 77 63
Hold
73
73 44 1
Lexicon Pharmaceuticals, Inc. 321.6M 51 69 77
Hold
61
61 45 1
Precigen, Inc. 299.1M 73 79 74
Buy
79
79 46 1
bluebird bio, Inc. 288.7M 50 96 83
Hold
78
78 47 1
Rigel Pharmaceuticals, Inc. 187.5M 62 64 41
Underperform
52
52 48 1
MacroGenics, Inc. 184.6M 47 71 65
Underperform
53
53 49 1
Exact Sciences Corporation 7.2B 47 62 56
Underperform
46
46 50 1
Amicus Therapeutics, Inc. 3.0B 56 58 85
Hold
61
61 51 1
CureVac N.V. 2.6B 57 74 90
Hold
70
70 52 1
Fate Therapeutics, Inc. 2.4B 53 46 61
Underperform
45
45 53 1
Abgenix Inc. 2.1B 67 47 58
Underperform
45
45 54 1
Xenon Pharmaceuticals Inc. 1.9B 61 56 89
Hold
64
64 55 1
Iovance Biotherapeutics, Inc. 1.7B 63 71 77
Hold
68
68 56 1
Xencor, Inc. 1.6B 67 79 98
Buy
82
82 57 1
Emergent BioSolutions Inc. 1.6B 61 66 75
Hold
65
65 58 1
Dynavax Technologies Corporation 1.5B 63 67 68
Hold
64
64 59 1
Ligand Pharmaceuticals Incorporated 1.5B 56 69 84
Hold
65
65 60 1
Aurinia Pharmaceuticals Inc. 1.4B 52 70 84
Hold
62
62 61 1
Veracyte, Inc. 1.4B 57 55 82
Underperform
59
59 62 1
Sierra Oncology, Inc. 1.3B 80 61 52
Hold
68
68 63 1
Celldex Therapeutics, Inc. 1.3B 57 70 69
Hold
61
61 64 1
CareDx, Inc 1.2B 52 50 86
Underperform
54
54 65 1
Vericel Corporation 1.1B 57 56 65
Underperform
53
53 66 1
Avid Bioservices, Inc. 959.5M 67 75 66
Hold
69
69 67 1
MannKind Corporation 957.2M 57 61 66
Underperform
56
56 68 1
Merus N.V. 941.6M 70 54 71
Hold
64
64 69 1
Sorrento Therapeutics, Inc. 747.5M 74 55 52
Hold
61
61 70 1
Amarin Corporation plc 734.5M 55 63 55
Underperform
52
52 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 75 77 87
Buy
84
84 72 1
Northwest Biotherapeutics, Inc. 682.9M 65 79 85
Hold
77
77 73 1
Organogenesis Holdings Inc. 612.1M 60 69 75
Hold
64
64 74 1
CTI BioPharma Corp. 603.6M 54 59 56
Underperform
50
50 75 1
Vanda Pharmaceuticals Inc. 598.8M 64 62 69
Hold
62
62 76 1
Eagle Pharmaceuticals, Inc. 546.4M 75 78 73
Buy
79
79 77 1
Immatics N.V. 538.7M 76 77 86
Buy
84
84 78 1
Agenus Inc. 520.5M 54 74 58
Underperform
57
57 79 1
Radius Health, Inc. 499.8M 54 82 57
Hold
61
61 80 1
Vaxart, Inc. 440.0M 53 68 65
Underperform
56
56 81 1
Affimed N.V. 415.0M 54 66 74
Underperform
59
59 82 1
ADMA Biologics, Inc. 396.6M 68 57 71
Hold
64
64 83 1
MiMedx Group, Inc. 391.5M 45 59 60
Underperform
45
45 84 1
Albireo Pharma, Inc. 362.9M 54 65 63
Underperform
55
55 85 1
AVEO Pharmaceuticals, Inc. 337.5M 66 74 95
Hold
78
78 86 1
Zymeworks Inc. 324.7M 62 56 57
Underperform
54
54 87 1
Heron Therapeutics, Inc. 314.6M 58 62 71
Underperform
59
59 88 1
Silence Therapeutics plc 313.4M 66 72 69
Hold
70
70 89 1
AC Immune SA 299.8M 68 70 68
Hold
68
68 90 1
Viridian Therapeutics, Inc. 293.2M 65 53 65
Underperform
56
56 91 1
Sutro Biopharma, Inc. 245.5M 61 56 74
Underperform
59
59 92 1
Chimerix, Inc. 178.4M 49 65 83
Underperform
58
58 93 1
DermTech, Inc. 165.3M 56 52 58
Underperform
47
47 94 1
Gelesis Holdings, Inc. 111.5M 78 39 80
Hold
66
66 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 49 61 58
Underperform
56
56 96 1
INSYS Therapeutics, Inc. 3.2M 43 70 73
Underperform
55
55 97 1

Technical Analysis

When trying to optimize the timing of an investment, it's critical to analyze whether the stock looks overbought or oversold, and in which direction the momentum is moving. Mirati Therapeutics's stock is now priced above its 5-day and 50-day, but below its 200-day moving average, while its MACD (moving average convergence divergence) indicates that the stock's price movement momentum is strengthening. Historically, this is a positive setup in both the short and medium-term. Meanwhile, looking at the Stochastic Oscillator and RSI (relative strength index), Mirati Therapeutics's stock doesn't strongly signal being overbought or oversold. Overall, these technical indicators don't clearly signal directional momentum. Therefore, this stock received a cumulative TA (technical analysis) score of 62.

Neutral 62
Close Price 68.5
52W Low 39.16
52W High 190.29
5D MA 67.04
50D MA 59.24
200D MA 112.39
MACD 2.51
RSI 37.33
STOCH 93.77

Balance Sheet Analysis

Mirati Therapeutics's most recent balance sheet report was not encouraging. Mirati Therapeutics publishes discouraging results related to book value factors in this report. As of the current filing, price to book ratio (P/B) was reported as 2.5, representing a -56.5% change from the previous report. This characteristic can affect companies in the same industry and market capitalization by up to 22.6%. They does not yet appear to be headed in the right direction to achieve strong book value metrics. Therefore, their book value factors earned a score of 42. Also, Mirati Therapeutics's management did a relatively poor job managing cash and cash equivalents, which now sit at 304.7 and represents a -26.2% change from the last reporting period. This performance is significantly less impressive than its peers and competitors. Consequently, their cash and cash equivalents movement received a grade of 48. On the other hand, Assets, jumped out as looking rather positive. Mirati Therapeutics assets on their balance sheet, moved to 1421.3, which is a -10.5% change from the last period. This growth should support upward pressure on its's stock price, which better captures their intrinsic value. The company's asset component, therefore, received a grade of 66. Because of these weaknesses, its balance sheet received an overall score of 50.

Parameter Value Change Score
Assets 1,421.3 -10.5% 66
Liabilities 172.0 -10.3% 53
Price to Book 2.5 -56.5% 42
Cash & Equivalents 304.7 -26.2% 48
Equity 1,249.3 -10.6% 57
* All values are TTM

The below chart describes Mirati Therapeutics's performance as reflected on its balance sheet with respect to its peers. While Mirati Therapeutics received a balance sheet score of 50, the average of its peers stands on 66.0.

  •  MRTX
  •  Peers average
Name Market Cap Liabilities Movement Asset Change Equity/Intangibles Adjustments Cash & Equivalents Book Value Momentum Balance Sheet mc_sort Hidden
Amgen Inc. 130.1B 72 68 86 53 62 69 0 1
Gilead Sciences, Inc. 78.0B 48 63 61 52 62 57 1 1
Vertex Pharmaceuticals Incorporated 70.6B 69 69 58 84 92 78 2 1
Regeneron Pharmaceuticals, Inc. 64.0B 48 65 52 86 81 67 3 1
BioNTech SE 34.0B 75 69 64 97 73 75 4 1
Seagen Inc. 32.9B 59 68 55 43 66 61 5 1
Biogen Inc. 29.7B 57 72 92 50 76 76 6 1
Alnylam Pharmaceuticals, Inc. 17.2B 50 66 46 44 61 54 7 1
Incyte Corporation 16.8B 71 72 95 82 79 83 8 1
BioMarin Pharmaceutical Inc. 15.4B 55 75 54 77 74 70 9 1
United Therapeutics Corporation 10.6B 61 74 58 60 88 76 10 1
Neurocrine Biosciences, Inc. 9.3B 67 69 55 51 78 68 11 1
Exelixis, Inc. 6.7B 53 66 57 84 81 70 12 1
Sarepta Therapeutics, Inc. 6.5B 68 69 49 41 58 58 13 1
Halozyme Therapeutics, Inc. 6.3B 59 68 65 72 85 74 14 1
Ionis Pharmaceuticals, Inc. 5.4B 59 68 58 43 67 62 15 1
Ascendis Pharma A/S 5.2B 51 70 85 94 54 68 16 1
Alkermes plc 5.0B 63 66 46 54 71 62 17 1
Cytokinetics, Incorporated 4.1B 49 79 42 76 62 64 18 1
Novavax, Inc. 4.0B 61 67 52 77 99 77 19 1
Natera, Inc. 3.6B 73 65 43 95 42 54 20 1
Arrowhead Pharmaceuticals, Inc. 3.4B 72 71 63 65 73 71 21 1
PTC Therapeutics, Inc. 2.8B 57 61 80 49 37 51 22 1
Insmed Incorporated 2.4B 49 65 45 46 63 55 23 1
ACADIA Pharmaceuticals Inc. 2.3B 83 65 55 91 55 63 24 1
BioCryst Pharmaceuticals, Inc. 1.9B 46 67 46 50 62 55 25 1
ChemoCentryx, Inc. 1.8B 72 77 47 53 52 61 26 1
Ironwood Pharmaceuticals, Inc. 1.8B 49 68 87 67 63 68 27 1
Myriad Genetics, Inc. 1.5B 51 62 51 43 57 52 28 1
Agios Pharmaceuticals, Inc. 1.2B 50 66 52 38 48 50 29 1
IVERIC bio, Inc. 1.1B 50 67 46 48 48 50 30 1
FibroGen, Inc. 1.0B 79 87 49 82 56 73 31 1
Syndax Pharmaceuticals, Inc. 1.0B 85 68 41 55 55 58 32 1
ImmunoGen, Inc. 946.1M 52 67 64 61 48 56 33 1
Enanta Pharmaceuticals, Inc. 922.8M 51 86 45 38 49 60 34 1
Deciphera Pharmaceuticals, Inc. 914.0M 56 71 38 82 63 61 35 1
Anavex Life Sciences Corp. 767.1M 50 67 50 75 66 61 36 1
Sangamo Therapeutics, Inc. 600.0M 59 64 47 45 46 48 37 1
AnaptysBio, Inc. 586.3M 85 63 41 37 51 52 38 1
Geron Corporation 566.2M 69 72 37 59 62 60 39 1
Mersana Therapeutics, Inc. 449.1M 75 68 39 82 52 58 40 1
Inovio Pharmaceuticals, Inc. 416.9M 56 66 38 54 40 46 41 1
Arbutus Biopharma Corporation 388.2M 86 65 61 48 55 60 42 1
Intercept Pharmaceuticals, Inc. 386.3M 46 68 57 41 61 57 43 1
Anika Therapeutics, Inc. 322.7M 76 68 63 64 65 64 44 1
Lexicon Pharmaceuticals, Inc. 321.6M 48 68 51 43 51 51 45 1
Precigen, Inc. 299.1M 81 85 61 72 48 73 46 1
bluebird bio, Inc. 288.7M 48 67 42 38 57 50 47 1
Rigel Pharmaceuticals, Inc. 187.5M 53 67 51 90 63 62 48 1
MacroGenics, Inc. 184.6M 53 64 61 37 39 47 49 1
Exact Sciences Corporation 7.2B 57 58 45 42 52 47 50 1
Amicus Therapeutics, Inc. 3.0B 52 64 58 66 56 56 51 1
CureVac N.V. 2.6B 49 64 75 52 52 57 52 1
Fate Therapeutics, Inc. 2.4B 63 70 54 39 45 53 53 1
Abgenix Inc. 2.1B 81 57 86 92 45 67 54 1
Xenon Pharmaceuticals Inc. 1.9B 48 69 53 45 70 61 55 1
Iovance Biotherapeutics, Inc. 1.7B 52 74 72 87 45 63 56 1
Xencor, Inc. 1.6B 53 78 60 40 67 67 57 1
Emergent BioSolutions Inc. 1.6B 48 62 87 48 61 61 58 1
Dynavax Technologies Corporation 1.5B 52 69 54 38 76 63 59 1
Ligand Pharmaceuticals Incorporated 1.5B 75 63 61 49 52 56 60 1
Aurinia Pharmaceuticals Inc. 1.4B 51 67 59 41 47 52 61 1
Veracyte, Inc. 1.4B 64 68 54 66 51 57 62 1
Sierra Oncology, Inc. 1.3B 62 71 52 97 97 80 63 1
Celldex Therapeutics, Inc. 1.3B 48 69 61 44 57 57 64 1
CareDx, Inc 1.2B 54 67 52 39 51 52 65 1
Vericel Corporation 1.1B 51 65 56 53 61 57 66 1
Avid Bioservices, Inc. 959.5M 75 61 61 58 72 67 67 1
MannKind Corporation 957.2M 79 59 50 40 64 57 68 1
Merus N.V. 941.6M 59 68 50 83 81 70 69 1
Sorrento Therapeutics, Inc. 747.5M 89 71 50 97 73 74 70 1
Amarin Corporation plc 734.5M 51 65 58 72 51 55 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 52 69 70 77 86 75 72 1
Northwest Biotherapeutics, Inc. 682.9M 65 63 48 38 86 65 73 1
Organogenesis Holdings Inc. 612.1M 59 66 56 66 60 60 74 1
CTI BioPharma Corp. 603.6M 84 70 37 92 37 54 75 1
Vanda Pharmaceuticals Inc. 598.8M 82 70 47 89 56 64 76 1
Eagle Pharmaceuticals, Inc. 546.4M 83 70 73 46 79 75 77 1
Immatics N.V. 538.7M 56 70 84 95 73 76 78 1
Agenus Inc. 520.5M 73 62 37 55 60 54 79 1
Radius Health, Inc. 499.8M 50 64 50 44 59 54 80 1
Vaxart, Inc. 440.0M 69 67 47 56 47 53 81 1
Affimed N.V. 415.0M 56 66 63 56 47 54 82 1
ADMA Biologics, Inc. 396.6M 74 68 49 77 72 68 83 1
MiMedx Group, Inc. 391.5M 53 66 42 57 37 45 84 1
Albireo Pharma, Inc. 362.9M 48 65 42 58 62 54 85 1
AVEO Pharmaceuticals, Inc. 337.5M 76 68 61 78 60 66 86 1
Zymeworks Inc. 324.7M 77 69 70 90 43 62 87 1
Heron Therapeutics, Inc. 314.6M 84 65 48 43 58 58 88 1
Silence Therapeutics plc 313.4M 58 71 69 63 59 66 89 1
AC Immune SA 299.8M 84 64 47 53 75 68 90 1
Viridian Therapeutics, Inc. 293.2M 56 72 44 37 76 65 91 1
Sutro Biopharma, Inc. 245.5M 82 69 56 66 49 61 92 1
Chimerix, Inc. 178.4M 48 63 46 95 40 49 93 1
DermTech, Inc. 165.3M 76 72 51 52 43 56 94 1
Gelesis Holdings, Inc. 111.5M 47 76 48 76 98 78 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 37 71 45 39 55 49 96 1
INSYS Therapeutics, Inc. 3.2M 48 70 44 90 37 43 97 1

Income Statement Analysis

Overall, Mirati Therapeutics's critical income statement metrics appear to signal strong support and a high likelihood of positive growth going forward. In this filing, Mirati Therapeutics reported a return on equity (ROE) ratio of -50.6, which represents a change of -19.9%. These numbers show that management has successfully encouraged growth while managing ROE and ROA metrics, especially relative to their peers. Consequently, their return factors received a grade of 78. Also, Mirati Therapeutics reported highly encouraging numbers for its revenue efficiency. This characteristic can affect companies in the same industry and market capitalization by up to 13.1%. Their revenue efficiency, specifically in contrast to their industry peers', should support a positive movement in the company's stock price. The company's revenue efficiency, therefore, received a grade of 76. On the other hand, EBITDA, jumped out as looking problematic. Mirati Therapeutics's management didn't make significant improvements to their EBITDA this period. In terms of the raw numbers, EBITDA was reported as -615.3, which represents a -9.1% change from the last period. This parameter coud affect companies in the same industry and market capitalization by up to 24.4%. Their EBITDA metrics are even more problematic when compared to their peers. Therefore, their EBITDA component earned a score of 55. Its income statement, therefore, earned a score of 64.

Parameter Value Change Score
EBITDA -615.3 -9.1% 55
Total Revenues 72.8 1.0% 76
Return on Equity -50.6 -19.9% 78
* All values are TTM

The below chart describes Mirati Therapeutics's performance as reflected on its income statement with respect to its peers. While Mirati Therapeutics received a income statement score of 64 , the average of its peers stands on 62.0.

  •  MRTX
  •  Peers average
Name Market Cap Revenue Momentum Earning Movement Return Factors Momentum Income Statement mc_sort Hidden
Amgen Inc. 130.1B 74 75 64 78 0 1
Gilead Sciences, Inc. 78.0B 78 71 52 73 1 1
Vertex Pharmaceuticals Incorporated 70.6B 57 80 62 75 2 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 66 74 3 1
BioNTech SE 34.0B 41 89 75 79 4 1
Seagen Inc. 32.9B 54 65 70 62 5 1
Biogen Inc. 29.7B 90 57 73 70 6 1
Alnylam Pharmaceuticals, Inc. 17.2B 60 86 56 80 7 1
Incyte Corporation 16.8B 59 77 60 73 8 1
BioMarin Pharmaceutical Inc. 15.4B 72 81 65 82 9 1
United Therapeutics Corporation 10.6B 57 91 54 82 10 1
Neurocrine Biosciences, Inc. 9.3B 53 54 77 55 11 1
Exelixis, Inc. 6.7B 54 91 54 81 12 1
Sarepta Therapeutics, Inc. 6.5B 49 89 55 78 13 1
Halozyme Therapeutics, Inc. 6.3B 53 84 85 82 14 1
Ionis Pharmaceuticals, Inc. 5.4B 62 94 53 86 15 1
Ascendis Pharma A/S 5.2B 38 68 46 54 16 1
Alkermes plc 5.0B 69 55 81 62 17 1
Cytokinetics, Incorporated 4.1B 95 50 73 66 18 1
Novavax, Inc. 4.0B 41 89 54 75 19 1
Natera, Inc. 3.6B 52 51 78 52 20 1
Arrowhead Pharmaceuticals, Inc. 3.4B 38 92 53 76 21 1
PTC Therapeutics, Inc. 2.8B 54 78 66 73 22 1
Insmed Incorporated 2.4B 51 58 73 57 23 1
ACADIA Pharmaceuticals Inc. 2.3B 72 49 80 58 24 1
BioCryst Pharmaceuticals, Inc. 1.9B 41 74 72 66 25 1
ChemoCentryx, Inc. 1.8B 97 57 71 73 26 1
Ironwood Pharmaceuticals, Inc. 1.8B 70 79 61 79 27 1
Myriad Genetics, Inc. 1.5B 89 93 57 96 28 1
Agios Pharmaceuticals, Inc. 1.2B 99 64 54 75 29 1
IVERIC bio, Inc. 1.1B 84 58 79 70 30 1
FibroGen, Inc. 1.0B 48 74 63 67 31 1
Syndax Pharmaceuticals, Inc. 1.0B 87 47 81 62 32 1
ImmunoGen, Inc. 946.1M 40 73 71 64 33 1
Enanta Pharmaceuticals, Inc. 922.8M 90 63 72 75 34 1
Deciphera Pharmaceuticals, Inc. 914.0M 60 79 70 77 35 1
Anavex Life Sciences Corp. 767.1M 84 69 60 75 36 1
Sangamo Therapeutics, Inc. 600.0M 72 72 73 76 37 1
AnaptysBio, Inc. 586.3M 97 50 77 68 38 1
Geron Corporation 566.2M 89 67 73 78 39 1
Mersana Therapeutics, Inc. 449.1M 37 54 72 47 40 1
Inovio Pharmaceuticals, Inc. 416.9M 96 57 68 72 41 1
Arbutus Biopharma Corporation 388.2M 37 82 53 67 42 1
Intercept Pharmaceuticals, Inc. 386.3M 71 93 40 86 43 1
Anika Therapeutics, Inc. 322.7M 63 80 62 77 44 1
Lexicon Pharmaceuticals, Inc. 321.6M 98 48 82 69 45 1
Precigen, Inc. 299.1M 57 87 59 79 46 1
bluebird bio, Inc. 288.7M 99 91 61 96 47 1
Rigel Pharmaceuticals, Inc. 187.5M 99 44 82 64 48 1
MacroGenics, Inc. 184.6M 95 56 74 71 49 1
Exact Sciences Corporation 7.2B 57 67 54 62 50 1
Amicus Therapeutics, Inc. 3.0B 61 55 77 58 51 1
CureVac N.V. 2.6B 45 83 71 74 52 1
Fate Therapeutics, Inc. 2.4B 45 52 61 46 53 1
Abgenix Inc. 2.1B 47 47 47 47 54 1
Xenon Pharmaceuticals Inc. 1.9B 41 65 59 56 55 1
Iovance Biotherapeutics, Inc. 1.7B 84 60 75 71 56 1
Xencor, Inc. 1.6B 42 94 52 79 57 1
Emergent BioSolutions Inc. 1.6B 91 51 77 66 58 1
Dynavax Technologies Corporation 1.5B 51 69 77 67 59 1
Ligand Pharmaceuticals Incorporated 1.5B 92 53 78 69 60 1
Aurinia Pharmaceuticals Inc. 1.4B 38 81 68 70 61 1
Veracyte, Inc. 1.4B 45 63 57 55 62 1
Sierra Oncology, Inc. 1.3B 84 54 54 61 63 1
Celldex Therapeutics, Inc. 1.3B 96 53 78 70 64 1
CareDx, Inc 1.2B 61 44 82 50 65 1
Vericel Corporation 1.1B 76 44 82 56 66 1
Avid Bioservices, Inc. 959.5M 49 82 69 75 67 1
MannKind Corporation 957.2M 95 48 56 61 68 1
Merus N.V. 941.6M 48 60 59 54 69 1
Sorrento Therapeutics, Inc. 747.5M 50 60 60 55 70 1
Amarin Corporation plc 734.5M 95 44 82 63 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 48 88 58 77 72 1
Northwest Biotherapeutics, Inc. 682.9M 43 90 65 79 73 1
Organogenesis Holdings Inc. 612.1M 89 55 79 69 74 1
CTI BioPharma Corp. 603.6M 84 50 62 59 75 1
Vanda Pharmaceuticals Inc. 598.8M 89 46 81 62 76 1
Eagle Pharmaceuticals, Inc. 546.4M 39 94 53 78 77 1
Immatics N.V. 538.7M 37 93 53 77 78 1
Agenus Inc. 520.5M 57 83 45 74 79 1
Radius Health, Inc. 499.8M 94 71 68 82 80 1
Vaxart, Inc. 440.0M 99 51 72 68 81 1
Affimed N.V. 415.0M 95 49 75 66 82 1
ADMA Biologics, Inc. 396.6M 43 65 62 57 83 1
MiMedx Group, Inc. 391.5M 87 43 83 59 84 1
Albireo Pharma, Inc. 362.9M 46 69 77 65 85 1
AVEO Pharmaceuticals, Inc. 337.5M 38 89 54 74 86 1
Zymeworks Inc. 324.7M 58 53 77 56 87 1
Heron Therapeutics, Inc. 314.6M 61 60 75 62 88 1
Silence Therapeutics plc 313.4M 83 64 69 72 89 1
AC Immune SA 299.8M 83 61 65 70 90 1
Viridian Therapeutics, Inc. 293.2M 55 50 63 53 91 1
Sutro Biopharma, Inc. 245.5M 60 47 80 56 92 1
Chimerix, Inc. 178.4M 99 50 62 65 93 1
DermTech, Inc. 165.3M 49 48 78 52 94 1
Gelesis Holdings, Inc. 111.5M 41 46 56 39 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 83 49 92 61 96 1
INSYS Therapeutics, Inc. 3.2M 97 48 63 70 97 1

Cash Flow Analysis

Mirati Therapeutics appears likely to maintain its strong cash flow metrics and momentum going forward. Mirati Therapeutics is doing a remarkable job of keeping its asset turnover under control. At filing, their asset turnover metrics were 0.1, representing a 10.5% change from the previous period. This metric might have a 4.1 percent impact on companies in the same industry and with the same market capitalization. Its asset turnover metrics are especially remarkable relative to their peers. We believe the stock price has room to grow to reflect its intrinsic value accurately. Therefore, its asset turnover movement earned a score of 89. Also, Mirati Therapeutics's management was effective in improving its CapEx, which now sits at -9.8 and represents -0.3% change from the previous report. This performance is all the more impressive relative to their peers and competitors. Therefore, its CapEx movement component earned a score of 71. On the other hand, Net Cash Flow, jumped out as looking problematic. Mirati Therapeutics's management was not successful in meaningfully improving their cash flow metrics. As of the current filing, they were reported as -24.8 and represented a 94.7% change from the previous period. Their net cash flow momentum should be a cause for concern and could bring negative momentum for Mirati Therapeutics's stock price going forward. Consequently, their net cash flow movement received a grade of 56. Consequently, the company's cash flow earned a score of 65.

Parameter Value Change Score
Net Cashflow -24.8 94.7% 56
Capital Expenditure -9.8 -0.3% 71
Asset Turnover 0.1 10.5% 89
Free Cashflow -8.5 -10.1% 58
* All values are TTM

The below chart describes Mirati Therapeutics's performance as reflected on its cash flow with respect to its peers. While Mirati Therapeutics received a cash flow score of 65, the average of its peers stands on 64.0.

  •  MRTX
  •  Peers average
Name Market Cap Cashflow Momentum Free Cashflow Growth Capital Expenditure Growth Assets Factors Momentum Cash Flow mc_sort Hidden
Amgen Inc. 130.1B 80 74 67 74 81 0 1
Gilead Sciences, Inc. 78.0B 57 61 53 85 62 1 1
Vertex Pharmaceuticals Incorporated 70.6B 64 75 80 71 71 2 1
Regeneron Pharmaceuticals, Inc. 64.0B 69 86 64 66 73 3 1
BioNTech SE 34.0B 73 97 50 52 72 4 1
Seagen Inc. 32.9B 53 53 50 87 58 5 1
Biogen Inc. 29.7B 58 54 90 73 66 6 1
Alnylam Pharmaceuticals, Inc. 17.2B 82 80 70 89 85 7 1
Incyte Corporation 16.8B 78 79 92 74 84 8 1
BioMarin Pharmaceutical Inc. 15.4B 59 48 66 77 63 9 1
United Therapeutics Corporation 10.6B 93 92 68 80 93 10 1
Neurocrine Biosciences, Inc. 9.3B 63 43 54 74 63 11 1
Exelixis, Inc. 6.7B 79 90 89 83 87 12 1
Sarepta Therapeutics, Inc. 6.5B 85 89 95 87 93 13 1
Halozyme Therapeutics, Inc. 6.3B 83 66 52 49 75 14 1
Ionis Pharmaceuticals, Inc. 5.4B 88 96 60 86 89 15 1
Ascendis Pharma A/S 5.2B 48 59 77 98 62 16 1
Alkermes plc 5.0B 89 95 76 80 92 17 1
Cytokinetics, Incorporated 4.1B 63 79 89 51 69 18 1
Novavax, Inc. 4.0B 62 38 63 54 60 19 1
Natera, Inc. 3.6B 52 54 56 84 58 20 1
Arrowhead Pharmaceuticals, Inc. 3.4B 60 39 87 96 70 21 1
PTC Therapeutics, Inc. 2.8B 72 53 54 83 72 22 1
Insmed Incorporated 2.4B 79 80 61 89 82 23 1
ACADIA Pharmaceuticals Inc. 2.3B 61 57 98 80 72 24 1
BioCryst Pharmaceuticals, Inc. 1.9B 61 58 54 96 67 25 1
ChemoCentryx, Inc. 1.8B 84 92 97 50 87 26 1
Ironwood Pharmaceuticals, Inc. 1.8B 77 66 67 76 78 27 1
Myriad Genetics, Inc. 1.5B 50 37 82 83 59 28 1
Agios Pharmaceuticals, Inc. 1.2B 85 68 44 46 75 29 1
IVERIC bio, Inc. 1.1B 64 67 44 71 64 30 1
FibroGen, Inc. 1.0B 86 74 48 87 84 31 1
Syndax Pharmaceuticals, Inc. 1.0B 50 41 74 78 57 32 1
ImmunoGen, Inc. 946.1M 77 79 95 95 87 33 1
Enanta Pharmaceuticals, Inc. 922.8M 58 47 84 83 66 34 1
Deciphera Pharmaceuticals, Inc. 914.0M 87 79 95 91 94 35 1
Anavex Life Sciences Corp. 767.1M 69 63 74 71 72 36 1
Sangamo Therapeutics, Inc. 600.0M 85 78 93 83 91 37 1
AnaptysBio, Inc. 586.3M 80 77 92 41 80 38 1
Geron Corporation 566.2M 78 68 49 81 77 39 1
Mersana Therapeutics, Inc. 449.1M 59 69 53 92 65 40 1
Inovio Pharmaceuticals, Inc. 416.9M 67 67 92 44 71 41 1
Arbutus Biopharma Corporation 388.2M 92 93 80 87 95 42 1
Intercept Pharmaceuticals, Inc. 386.3M 87 95 98 89 96 43 1
Anika Therapeutics, Inc. 322.7M 69 67 70 51 63 44 1
Lexicon Pharmaceuticals, Inc. 321.6M 91 82 39 46 77 45 1
Precigen, Inc. 299.1M 82 75 37 85 74 46 1
bluebird bio, Inc. 288.7M 89 77 93 37 83 47 1
Rigel Pharmaceuticals, Inc. 187.5M 42 40 46 40 41 48 1
MacroGenics, Inc. 184.6M 70 53 54 46 65 49 1
Exact Sciences Corporation 7.2B 53 45 80 46 56 50 1
Amicus Therapeutics, Inc. 3.0B 81 80 71 87 85 51 1
CureVac N.V. 2.6B 87 80 90 70 90 52 1
Fate Therapeutics, Inc. 2.4B 64 52 55 48 61 53 1
Abgenix Inc. 2.1B 66 53 45 59 58 54 1
Xenon Pharmaceuticals Inc. 1.9B 82 77 87 92 89 55 1
Iovance Biotherapeutics, Inc. 1.7B 77 66 69 69 77 56 1
Xencor, Inc. 1.6B 96 95 70 95 98 57 1
Emergent BioSolutions Inc. 1.6B 70 53 87 75 75 58 1
Dynavax Technologies Corporation 1.5B 64 48 82 65 68 59 1
Ligand Pharmaceuticals Incorporated 1.5B 86 93 51 78 84 60 1
Aurinia Pharmaceuticals Inc. 1.4B 73 79 92 96 84 61 1
Veracyte, Inc. 1.4B 90 95 46 46 82 62 1
Sierra Oncology, Inc. 1.3B 47 77 38 71 52 63 1
Celldex Therapeutics, Inc. 1.3B 69 63 67 54 69 64 1
CareDx, Inc 1.2B 98 84 40 50 86 65 1
Vericel Corporation 1.1B 64 46 59 73 65 66 1
Avid Bioservices, Inc. 959.5M 80 38 40 50 66 67 1
MannKind Corporation 957.2M 77 56 43 37 66 68 1
Merus N.V. 941.6M 70 71 74 53 71 69 1
Sorrento Therapeutics, Inc. 747.5M 48 63 61 52 52 70 1
Amarin Corporation plc 734.5M 52 40 74 55 55 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 77 81 98 87 87 72 1
Northwest Biotherapeutics, Inc. 682.9M 80 77 81 86 85 73 1
Organogenesis Holdings Inc. 612.1M 76 76 63 55 75 74 1
CTI BioPharma Corp. 603.6M 48 60 74 67 56 75 1
Vanda Pharmaceuticals Inc. 598.8M 66 60 87 51 69 76 1
Eagle Pharmaceuticals, Inc. 546.4M 63 40 97 92 73 77 1
Immatics N.V. 538.7M 82 95 56 99 86 78 1
Agenus Inc. 520.5M 57 43 52 77 58 79 1
Radius Health, Inc. 499.8M 64 40 37 56 57 80 1
Vaxart, Inc. 440.0M 72 56 53 38 65 81 1
Affimed N.V. 415.0M 72 57 95 43 74 82 1
ADMA Biologics, Inc. 396.6M 62 77 74 85 71 83 1
MiMedx Group, Inc. 391.5M 46 48 97 86 60 84 1
Albireo Pharma, Inc. 362.9M 59 68 41 95 63 85 1
AVEO Pharmaceuticals, Inc. 337.5M 94 87 74 83 95 86 1
Zymeworks Inc. 324.7M 52 65 45 83 57 87 1
Heron Therapeutics, Inc. 314.6M 66 74 61 84 71 88 1
Silence Therapeutics plc 313.4M 68 66 72 69 69 89 1
AC Immune SA 299.8M 66 77 79 63 68 90 1
Viridian Therapeutics, Inc. 293.2M 72 87 43 45 65 91 1
Sutro Biopharma, Inc. 245.5M 83 67 64 50 74 92 1
Chimerix, Inc. 178.4M 80 84 95 47 83 93 1
DermTech, Inc. 165.3M 60 51 45 86 58 94 1
Gelesis Holdings, Inc. 111.5M 64 90 92 98 80 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 58 72 43 71 58 96 1
INSYS Therapeutics, Inc. 3.2M 75 78 87 52 73 97 1

This report is intended for general guidance and information purposes only and under no circumstances is tailored to a specific factor or variable related to its reader or intended to be used or considered as financial or investment advice, a solicitation of any offer, a recommendation, or an offer to sell or buy any securities or other form of a financial asset. For the full disclaimer, click here.